DiaSorin (DIA) Stock Overview
Engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
DIA passed our risk checks.
DIA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
DiaSorin S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €69.32 |
| 52 Week High | €92.32 |
| 52 Week Low | €52.34 |
| Beta | 0.70 |
| 1 Month Change | 7.37% |
| 3 Month Change | 9.54% |
| 1 Year Change | -23.40% |
| 3 Year Change | -25.77% |
| 5 Year Change | -59.78% |
| Change since IPO | 459.94% |
Recent News & Updates
Narrative Update • Jul 08
DIA: Reset Expectations Will Support Upside As Medium Term Guidance Firms
Analysts have reduced the DiaSorin fair value estimate from €105.00 to €81.30, reflecting lower assumed growth, margins and P/E multiples, which are broadly in line with recent price target cuts and more cautious views across several broker updates. Analyst Commentary Recent research on DiaSorin reflects a mix of caution and select optimism, with price targets clustered in a relatively tight range and differing views on the company’s ability to execute on its growth framework and capitalise on its diagnostics platforms.
Narrative Update • Jun 24
DIA: 2026 Guidance Reset Risk Will Drive Further Downside Skew
Analysts have trimmed their DiaSorin price expectations, with one key target moving from €62 to €58. They point to potential pressure on 2026 guidance and question the growth assumptions around the Liaison Nes platform.Narrative Update • Jun 06
DIA: Repeated Downgrades And Index Removal Will Skew Risk To Downside
DiaSorin’s updated analyst price target has decreased by €3, as analysts factor in a series of recent target cuts from major banks, while keeping underlying fair value assumptions broadly unchanged. Analyst Commentary Recent research has leaned more cautious on DiaSorin, with multiple bearish analysts trimming price targets and, in at least one case, downgrading their stance on the stock.Recent updates
Narrative Update • Jul 08
DIA: Reset Expectations Will Support Upside As Medium Term Guidance Firms
Analysts have reduced the DiaSorin fair value estimate from €105.00 to €81.30, reflecting lower assumed growth, margins and P/E multiples, which are broadly in line with recent price target cuts and more cautious views across several broker updates. Analyst Commentary Recent research on DiaSorin reflects a mix of caution and select optimism, with price targets clustered in a relatively tight range and differing views on the company’s ability to execute on its growth framework and capitalise on its diagnostics platforms.Narrative Update • Jun 24
DIA: 2026 Guidance Reset Risk Will Drive Further Downside Skew
Analysts have trimmed their DiaSorin price expectations, with one key target moving from €62 to €58. They point to potential pressure on 2026 guidance and question the growth assumptions around the Liaison Nes platform.Narrative Update • Jun 06
DIA: Repeated Downgrades And Index Removal Will Skew Risk To Downside
DiaSorin’s updated analyst price target has decreased by €3, as analysts factor in a series of recent target cuts from major banks, while keeping underlying fair value assumptions broadly unchanged. Analyst Commentary Recent research has leaned more cautious on DiaSorin, with multiple bearish analysts trimming price targets and, in at least one case, downgrading their stance on the stock.Narrative Update • May 23
DIA: Recent Downgrades Will Keep Risk Or Reward Skewed To Downside
Analysts have trimmed their price targets on DiaSorin by a few euros, citing updated views on earnings quality and valuation, even as underlying model assumptions for revenue growth and profit margins remain broadly steady. Analyst Commentary Recent research updates on DiaSorin have leaned cautious, with several bearish analysts cutting price targets by a few euros and signaling reduced confidence in the risk or reward profile, even as core revenue and margin assumptions largely hold.Analysis Article • May 13
Here's What Analysts Are Forecasting For DiaSorin S.p.A. (BIT:DIA) After Its First-Quarter Results
It's been a pretty great week for DiaSorin S.p.A. ( BIT:DIA ) shareholders, with its shares surging 10% to €68.28 in...Analysis Article • Mar 30
DiaSorin's (BIT:DIA) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from DiaSorin S.p.A. ( BIT:DIA ) was disappointing for shareholders. While the headline...Analysis Article • Mar 25
DiaSorin S.p.A. (BIT:DIA) Just Reported Earnings, And Analysts Cut Their Target Price
DiaSorin S.p.A. ( BIT:DIA ) shareholders are probably feeling a little disappointed, since its shares fell 9.7% to...Narrative Update • Feb 02
DIA: Slower Earnings Conversion And Margin Strain Will Keep Upside Limited
Analysts have trimmed DiaSorin's Street price target to €68 from €75.40, reflecting updated views on its revenue growth, margin outlook and appropriate future P/E multiple. Analyst Commentary Recent research points to a more cautious tone around DiaSorin, with the reduced Street price target to €68 reflecting reassessments of revenue resilience, margin durability and what investors may be willing to pay on a P/E basis.
Narrative Update • Jan 19
DIA: Fair Outlook Will Persist As Recent Caution Resets Expectations
Analysts have lowered their price target on DiaSorin from about €92.50 to roughly €81.39. This reflects more cautious assumptions on fair value after recent Street research, including a cut in the target price to €68.00 by a major bank.Analysis Article • Jan 19
These 4 Measures Indicate That DiaSorin (BIT:DIA) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Jan 05
DIA: Reset Expectations Will Support Medium Term Execution-Driven Upside Potential
Analysts have trimmed their price expectations for DiaSorin, with our fair value estimate moving from €122.00 to €105.00 after a recent cut in Street targets to €68.00. This reflects updated views on growth, margins and the appropriate discount rate.Narrative Update • Dec 16
DIA: Execution And Margin Pressures Will Shape A More Muted Outlook
Analysts have cut their fair value estimate for DiaSorin to EUR 58 from about EUR 78. This reflects a lower assumed future price to earnings multiple and reduced margin expectations, despite slightly higher projected revenue growth, in line with recent Street target reductions.Narrative Update • Dec 02
DIA: Medium Term Upside Will Persist Despite Near Term Market Caution
Analysts have lowered their price target for DiaSorin from €75.40 to €68. They cite updated market models and slightly reduced growth projections as the primary reasons for this downward revision.Narrative Update • Nov 18
DIA: Medium Term Potential Will Outweigh Competitive Pressures Through 2026
Analysts have lowered their fair value estimate for DiaSorin from approximately EUR 104 to EUR 95. They cite ongoing headwinds and modestly reduced growth forecasts as the rationale for the change.Analysis Article • Oct 02
These 4 Measures Indicate That DiaSorin (BIT:DIA) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Aug 18
Getting In Cheap On DiaSorin S.p.A. (BIT:DIA) Is Unlikely
BIT:DIA 1 Year Share Price vs Fair Value Explore DiaSorin's Fair Values from the Community and select yours With a...Analysis Article • Aug 03
DiaSorin S.p.A. (BIT:DIA) Just Released Its Interim Earnings: Here's What Analysts Think
DiaSorin S.p.A. ( BIT:DIA ) shareholders are probably feeling a little disappointed, since its shares fell 4.8% to...Analysis Article • Jul 29
A Look At The Intrinsic Value Of DiaSorin S.p.A. (BIT:DIA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, DiaSorin fair value estimate is €85.19 DiaSorin's €90.22 share...Analysis Article • Jun 20
DiaSorin (BIT:DIA) Has A Rock Solid Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Mar 20
DiaSorin's (BIT:DIA) Upcoming Dividend Will Be Larger Than Last Year's
The board of DiaSorin S.p.A. ( BIT:DIA ) has announced that it will be paying its dividend of €1.20 on the 21st of May...Analysis Article • Mar 16
Is DiaSorin (BIT:DIA) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Narrative • Dec 04
MeMed, LIAISON PLEX, And Global Expansion Set To Boost Revenue And Earnings Growth
Strong hospital strategy and new product offerings in the U.S. could drive significant revenue growth and new hospital additions.Analysis Article • Nov 29
Is DiaSorin (BIT:DIA) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Nov 08
DiaSorin S.p.A. (BIT:DIA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Investors in DiaSorin S.p.A. ( BIT:DIA ) had a good week, as its shares rose 9.0% to close at €109 following the...Analysis Article • Aug 23
DiaSorin S.p.A. (BIT:DIA) Investors Are Less Pessimistic Than Expected
With a price-to-earnings (or "P/E") ratio of 32.2x DiaSorin S.p.A. ( BIT:DIA ) may be sending very bearish signals at...Analysis Article • Aug 01
DiaSorin S.p.A. (BIT:DIA) Just Released Its Interim Results And Analysts Are Updating Their Estimates
Last week, you might have seen that DiaSorin S.p.A. ( BIT:DIA ) released its interim result to the market. The early...Analysis Article • Jul 16
We Think DiaSorin (BIT:DIA) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Apr 09
DiaSorin's (BIT:DIA) Dividend Will Be Increased To €1.15
The board of DiaSorin S.p.A. ( BIT:DIA ) has announced that it will be paying its dividend of €1.15 on the 22nd of May...Analysis Article • Mar 25
DiaSorin (BIT:DIA) Is Paying Out A Larger Dividend Than Last Year
DiaSorin S.p.A. ( BIT:DIA ) will increase its dividend from last year's comparable payment on the 22nd of May to €1.15...Analysis Article • Mar 20
DiaSorin S.p.A. (BIT:DIA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Last week, you might have seen that DiaSorin S.p.A. ( BIT:DIA ) released its annual result to the market. The early...Analysis Article • Feb 17
DiaSorin S.p.A.'s (BIT:DIA) Intrinsic Value Is Potentially 19% Below Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, DiaSorin fair value estimate is €72.70 DiaSorin is estimated...Analysis Article • Jan 25
Is DiaSorin (BIT:DIA) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Nov 11
Some May Be Optimistic About DiaSorin's (BIT:DIA) Earnings
Soft earnings didn't appear to concern DiaSorin S.p.A.'s ( BIT:DIA ) shareholders over the last week. Our analysis...Analysis Article • Oct 11
DiaSorin S.p.A.'s (BIT:DIA) Intrinsic Value Is Potentially 24% Below Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, DiaSorin fair value estimate is €67.40 DiaSorin is estimated...Analysis Article • Sep 19
Is DiaSorin (BIT:DIA) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • May 01
Does DiaSorin (BIT:DIA) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Apr 02
DiaSorin (BIT:DIA) Is Increasing Its Dividend To €1.10
DiaSorin S.p.A.'s ( BIT:DIA ) dividend will be increasing from last year's payment of the same period to €1.10 on 24th...Analysis Article • Jan 07
Does DiaSorin (BIT:DIA) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Sep 13
These 4 Measures Indicate That DiaSorin (BIT:DIA) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 17
Are DiaSorin S.p.A. (BIT:DIA) Investors Paying Above The Intrinsic Value?
Does the August share price for DiaSorin S.p.A. ( BIT:DIA ) reflect what it's really worth? Today, we will estimate the...Analysis Article • Jun 14
DiaSorin (BIT:DIA) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • May 19
DiaSorin (BIT:DIA) Will Pay A Larger Dividend Than Last Year At €1.05
DiaSorin S.p.A. ( BIT:DIA ) will increase its dividend on the 25th of May to €1.05. Despite this raise, the dividend...Analysis Article • May 03
DiaSorin's (BIT:DIA) Shareholders Will Receive A Bigger Dividend Than Last Year
DiaSorin S.p.A.'s ( BIT:DIA ) dividend will be increasing to €1.05 on 25th of May. Despite this raise, the dividend...Analysis Article • May 01
Calculating The Fair Value Of DiaSorin S.p.A. (BIT:DIA)
Does the May share price for DiaSorin S.p.A. ( BIT:DIA ) reflect what it's really worth? Today, we will estimate the...Shareholder Returns
| DIA | IT Medical Equipment | IT Market | |
|---|---|---|---|
| 7D | 0.7% | 1.3% | -0.5% |
| 1Y | -23.4% | -12.0% | 24.2% |
Return vs Industry: DIA underperformed the Italian Medical Equipment industry which returned -11.4% over the past year.
Return vs Market: DIA underperformed the Italian Market which returned 25.4% over the past year.
Price Volatility
| DIA volatility | |
|---|---|
| DIA Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 5.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in IT Market | 8.1% |
| 10% least volatile stocks in IT Market | 3.0% |
Stable Share Price: DIA has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: DIA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,242 | Carlo Rosa | int.diasorin.com |
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens.
DiaSorin S.p.A. Fundamentals Summary
| DIA fundamental statistics | |
|---|---|
| Market cap | €3.67b |
| Earnings (TTM) | €141.62m |
| Revenue (TTM) | €1.17b |
25.9x
P/E Ratio3.1x
P/S RatioIs DIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIA income statement (TTM) | |
|---|---|
| Revenue | €1.17b |
| Cost of Revenue | €409.54m |
| Gross Profit | €759.51m |
| Other Expenses | €617.89m |
| Earnings | €141.62m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 31, 2026
| Earnings per share (EPS) | 2.67 |
| Gross Margin | 64.97% |
| Net Profit Margin | 12.11% |
| Debt/Equity Ratio | 47.5% |
How did DIA perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield45%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/17 23:16 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DiaSorin S.p.A. is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Gaurav Jain | Barclays |
| Charles Pitman | Barclays |